Search Results

Your search for Rowan T. Chlebowski, MD, PhD, FASCO matches 2 pages

Showing 1 - 2

By Jo Cavallo / June 25, 2024 / 2024 ASCO Annual Meeting

Estrogen Alone Increased Ovarian Cancer Incidence and Mortality, Combination Hormone Therapy Did Not

In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause increased the ...

lung cancer

By Rowan T. Chlebowski, MD, PhD, FASCO / July 25, 2017

Adding Pravastatin to Chemotherapy in Small Cell Lung Cancer

Following early reports associating favorable outcomes in cancer patients with the use of statins,1,2 further observational studies in this area have provided mixed findings.3 As recently reported in the Journal of Clinical Oncology, and reviewed in this issue of The ASCO Post, Seckl and colleagues ...

Nov

Today In Oncology

Search Results

Your search for Rowan T. Chlebowski, MD, PhD, FASCO matches 2 pages

Estrogen Alone Increased Ovarian Cancer Incidence and Mortality, Combination Hormone Therapy Did Not

Adding Pravastatin to Chemotherapy in Small Cell Lung Cancer

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma